Prokidney (PROK) EBT (2021 - 2026)
Prokidney (PROK) posted quarterly EBT of -$42.6 million for Q1 2026, down 14.08% year-over-year from -$49.6 million in Q1 2025, and little changed quarter-over-quarter from -$42.4 million in Q4 2025.
Prokidney (PROK) EBT (2021 - 2026) Analysis & Trends
Prokidney (PROK) has reported EBT for 6 consecutive years, with -$42.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 14.08% year-over-year to -$42.6 million; the TTM figure through Mar 2026 stood at -$156.5 million (up 5.78% YoY), while the FY2025 annual figure was -$151.2 million, up 7.77% from the prior year.
- EBT was little changed at -$42.6 million in Q1 2026 per PROK's latest filing, from -$42.4 million in the prior quarter.
- Across five years, EBT topped out at -$18.9 million in Q4 2023 and bottomed at -$66.5 million in Q1 2022.
- Historically, EBT has averaged -$37.3 million across 5 years, with a median of -$36.1 million in 2025.
- Annual changes were most pronounced in 2022 — EBT slumped 1282725.16% — and 2023, when it jumped 46.47%.
- Prokidney's EBT stood at -$25.8 million in 2022, then rose by 26.72% to -$18.9 million in 2023, then sank by 147.09% to -$46.8 million in 2024, then grew by 9.29% to -$42.4 million in 2025, then declined by 0.43% to -$42.6 million in 2026.
- Business Quant data shows PROK's EBT at -$42.6 million in Q1 2026, -$42.4 million in Q4 2025, and -$35.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Prokidney | 679.95 Mn | 679.95 Mn | - | -46.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -46.44 Mn |
| Mar 31, 2026 | -42.62 Mn |
| Dec 31, 2025 | -42.44 Mn |
| Sep 30, 2025 | -35.28 Mn |
| Jun 30, 2025 | -36.12 Mn |
| Mar 31, 2025 | -37.36 Mn |
| Dec 31, 2024 | -46.78 Mn |
| Sep 30, 2024 | -43.40 Mn |
| Jun 30, 2024 | -38.52 Mn |
| Mar 31, 2024 | -35.24 Mn |
| Dec 31, 2023 | -18.93 Mn |
| Sep 30, 2023 | -41.08 Mn |
| Jun 30, 2023 | -33.86 Mn |
| Mar 31, 2023 | -35.58 Mn |
| Dec 31, 2022 | -25.84 Mn |
| Sep 30, 2022 | -34.02 Mn |
| Jun 30, 2022 | -20.91 Mn |
| Mar 31, 2022 | -66.48 Mn |
| Dec 31, 2021 | -13.71 Mn |
| Sep 30, 2021 | -17.08 Mn |